Table 3.
Overview of clinical trials for B-cell malignancies using CAR technology.
| Institution | Trial ID (disease) | Cohort age | Target | scFv (clone) | Spacer | Trans-membrane domain | Construct | Cell origin | Trans-duction platform | References |
|---|---|---|---|---|---|---|---|---|---|---|
| Autologous T cells | ||||||||||
| Baylor College of Medicine | NCT01853631 (B, C, N) | P/A | CD19 | FMC63 | CH2-CH3 | CD28 | CD28. 4-1BB.CD3ζ | Auto T cells | Retroviral | (11) |
| Baylor College of Medicine | NR | NR | CD19 | FMC63 | CH2-CH3 | CD4 | CD3ζ | Auto T cells | Retroviral | (77) |
| Baylor College of Medicine | NR | NR | CD19 | FMC63 | CH2-CH3 | CD28 | CD28.CD3ζ | Auto T cells | Retroviral | – |
| Bambino Gesù Children's Hospital | NCT03373071 (B, N) | P/yA | CD19 | FMC63 | CD8 | CD8 | 4-1BB.CD3ζ+iC9 | Auto T cells | Retroviral | – |
| City of Hope | BB-IND-11411 (N) | A | CD19 | FMC63 | CH2-CH3 | CD4 | CD3ζ | Auto T cells | Electro-poration | – |
| Fred Hutchinson Cancer Research Centre | NCT01865617 (B, C, N) | yA/A | CD19 | FMC63 | IgG4 | CD28 | 4-1BB.CD3ζ+EGFR | Auto T cells | Lentiviral | (39) |
| Guangdong Provincial People's Hospital | NCT02822326 (B) | P/yA/A | CD19 | FMC63 | NR | CD28 | CD28.CD3ζ+TLR2 | Auto T cells | Lentiviral | (78) |
| Hebei Senlang Biotechnology | NCT02963038 (B, N) | P/yA/A | CD19 | FMC63 | NR | NR | CD28. 4-1BB.CD3ζ+EGFR | Auto T cells | Lentiviral | (79) |
| Kite, A Gilead Company | NCT02614066 (B) | yA/A | CD19 | FMC63 | CD28 | CD28 | CD28.CD3ζ | Auto T cells | Retroviral | (80) |
| MD Anderson Cancer Centre | NCT01497184 (B, C, N) | P/yA/A | CD19 | FMC63 | NR | NR | CD28.CD3ζ | Auto T cells | Electro-poration | – |
| Memorial Sloan Kettering Cancer Centre | NCT01044069 (B-, C) | yA/A | CD19 | SJ25C1 | CD28 | CD28 | CD28.CD3ζ | Auto T cells | Retroviral | (41) |
| Memorial Sloan Kettering Cancer Centre | NCT01860937 (B) | P/yA | CD19 | SJ25C1 | CD28 | CD28 | CD28.CD3ζ | Auto T cells | Retroviral | (16) |
| National Cancer Institute | NCT00924326 (N) | yA/A | CD19 | FMC63 | CD28 | CD28 | CD28.CD3ζ | Auto T cells | Retroviral | (52, 81) |
| National Cancer Institute | NCT01593696 (B, N) | P/yA | CD19 | FMC63 | CD28 | CD28 | CD28.CD3ζ | Auto T cells | Retroviral | (18) |
| Seattle Children's Hospital | NCT02028455 (B) | P/yA | CD19 | FMC63 | NR | NR | 4-1BB.CD3ζ+EGFR | Auto T cells | Lentiviral | (82) |
| Sheba Medical Centre | NCT02772198 (B, N) | P/yA/A | CD19 | FMC63 | CD28 | CD28 | CD28.CD3ζ | Auto T cells | Retroviral | (83) |
| Southwest Hospital | NCT02349698 (B, C, N, H) | P/yA/A | CD19 | Humanised | CD8 | CD8 | 4-1BB.CD3ζ | Auto T cells | Lentiviral | (84, 85) |
| University College London | NCT02443831 (B, N) | P/yA | CD19 | CAT | CD8 | CD8 | 4-1BB.CD3ζ | Auto T cells | Lentiviral | (25) |
| University of Pennsylvania | NCT01029366 (B, C, N) | yA/A | CD19 | FMC63 | CD8 | CD8 | 4-1BB.CD3ζ | Auto T cells | Lentiviral | (22, 86) |
| University of Pennsylvania | NCT01626495 (B, C, N, H) | P/yA | CD19 | FMC63 | CD8 | CD8 | 4-1BB.CD3ζ | Auto T cells | Lentiviral | (13) |
| University of Pennsylvania | NCT02374333 (B, N) | P/yA | CD19 | Humanised | CD8 | CD8 | 4-1BB.CD3ζ | Auto T cells | Lentiviral | (87) |
| University of Pennsylvania | NCT02435849 (B) | P/yA | CD19 | FMC63 | CD8 | CD8 | 4-1BB.CD3ζ | Auto T cells | Lentiviral | (12) |
| Uppsala University | NCT02132624 (B, C, N, H) | yA/A | CD19 | NR | CH2-CH3 | CD28 | CD28. 4-1BB.CD3ζ | Auto T cells | Retroviral | (62) |
| Wuhan Sian Medical Technology Co. | NCT02965092 (B, N, H) | P/yA/A | CD19 | NR | NR | NR | 4-1BB.CD3ζ | Auto T cells | Lentiviral | (88) |
| Xuzhou Medical University | NCT02782351 (C) | P/yA/A | CD19 | Humanised | CD8 | CD8 | 4-1BB.CD3ζ+EGFR | Auto T cells | Lentiviral | (89) |
| Zhejiang University | ChiCTR-OCC-15007008 (B, N, H) | P/yA/A | CD19 | FMC63 | NR | NR | 4-1BB.CD3ζ | Auto T cells | Lentiviral | (90) |
| Hospital Clínic/ Hospital Sant Joan de Déu de Barcelona | NCT03144583 (B, C, N) | P/yA/A | CD19 | A3B1 | CD8 | CD8 | 4-1BB.CD3ζ | Auto T cells | Lentiviral | (91, 92) |
| Chinese PLA General Hospital | NCT03097770 (B, C, N) | P/yA/A | CD19/CD20 | FMC63+Leu16 | CD8 | CD8 | 4-1BB.CD3ζ | Auto T cells | Lentiviral | (93) |
| Medical College of Wisconsin | NCT03019055 (C, N) | yA/A | CD19/CD20 | NR | NR | NR | 4-1BB.CD3ζ | Auto T cells | Lentiviral | (94) |
| Chinese PLA General Hospital | NCT03185494 (B, C, N) | P/yA/A | CD19/CD22 | FMC63+m971 | NR | CD8 | 4-1BB.CD3ζ | Auto T cells | Lentiviral | (95) |
| Hebei Yanda Ludaopei Hospital | NCT04129099 (B) | P/yA/A | CD19/CD22 | FMC63+m971 | NR | CD8 | 4-1BB.CD3ζ | Auto T cells | Lentiviral | (96) |
| City of Hope | BB-IND-8513 (N) | A | CD20 | Leu-16 | CH2-CH3 | CD4 | CD3ζ | Auto T cells | Electro-poration | (97) |
| Beijing Boren Hospital | NR | NR | CD22 | Humanised | NR | CD8 | 4-1BB.CD3ζ | Auto T cells | Lentiviral | (98) |
| National Cancer Institute | NCT02315612 (B, N) | P/yA/A | CD22 | Humanised | NR | CD8 | 4-1BB.CD3ζ | Auto T cells | Retroviral | (29) |
| Baylor College of Medicine | NCT00881920 (C, N, MM) | yA/A | κ light chain | FMC63 | CH2-CH3 | CD28 | CD28.CD3ζ | Auto T cells | Retroviral | (99) |
| Allogenic T cells | ||||||||||
| Children's Hospital of Fudan University | NCT04173988 (B) | P | CD19 | NR | NR | NR | NR | Allo T cells | Lentiviral | – |
| Chinese PLA General Hospital | NCT01864889 (B-, C, N) | A | CD19 | HM852952 | CD8 | CD8 | 4-1BB.CD3ζ | Allo T cells | Lentiviral | (100) |
| Institut de Recherches Internationales Servier | NCT02808442 (B) | yA/A | CD19 | NR | NR | NR | 4-1BB.CD3ζ+ΔCD20 | Allo T cells (αTCR/CD52 depleted) | Lentiviral | (101) |
| MD Anderson Cancer Centre | NCT00968760 (N) | yA/A | CD19 | FMC63 | NR | NR | CD28.CD3ζ | Allo T cells | Electro-poration | (102) |
| National Cancer Institute | NCT01087294 (B, N, H) | yA/A | CD19 | FMC63 | CD28 | CD28 | CD28.CD3ζ | Allo T cells | Retroviral | (103) |
| Peking University | NCT03050190 (B malignancy) | P/yA/A | CD19 | FMC63 | NR | NR | CD28.CD27.CD3ζ+IC9 | Allo T cells | Lentiviral | (104) |
| Chinese PLA General Hospital | NCT03398967 (B, C, N, H) | P/yA/A | CD19/ CD20 or CD22 |
4G7 | NR | NR | 4-1BB.CD3ζ+ΔCD20 | Allo T cells (αTCR/CD52 depleted) | Lentiviral | (105) |
| Baylor College of Medicine | NCT00840853 (B, C, N) | P/yA/A | CD19+ Tri specific virus | FMC63 | CH2-CH3 | CD28 | CD28.CD3ζ | Allo T cells | Retroviral | (106) |
| Precision BioSciences | NCT04030195 (C, N) | yA/A | CD20 | NR | NR | NR | NR | Allo T cells | NR | – |
| The First Affiliated Hospital with Nanjing Medical University | NCT04176913 (N) | yA/A | CD20 | NR | NR | NR | NR | Allo T cells | NR | – |
| Cellectis S.A. | NCT04150497 (B) | P/yA/A | CD22 | NR | NR | NR | 4-1BB.CD3ζ | Allo T cells (αTCR/CD52 depleted) | Lentiviral | (107) |
| NK cells | ||||||||||
| Fate Therapeutics | NCT04245722 (C, N) | yA/A | CD19 | NR | NR | NR | NR | NK cells (iPSC) | NR | – |
| MD Anderson Cancer Centre | NCT03056339 (B, C, N) | P/yA/A | CD19 | FMC63 | CD28 | CD28 | CD28.CD3ζ+IL15 | NK cells (cord blood) | Retroviral | (108) |
A, Adult; Allo, allogeneic; Auto, autologous; B, B-cell precursor acute lymphoblastic leukaemia; CAR, chimeric antigen receptor; C, chronic lymphoblastic leukaemia; H, Hodgkin lymphoma; IgG4, immunoglobulin 4; iPSC, induced pluripotent stem cells; MM, multiple myeloma; N, non-Hodgkin lymphoma; NK, natural killer; NR, not reported; P, Paediatric; yA: young adult.